Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
NKGen Biotech ( (NKGN) ) just unveiled an update.
On May 5, 2025, NKGen Biotech entered into a Stock Purchase Agreement with its CEO and Chairperson, Paul Y. Song, involving the sale of 20,849,725 shares and warrants to purchase additional shares, valued at $2.65 million. This investment aims to accelerate the company’s Phase 2 clinical trial for Alzheimer’s Disease and address financial obligations. The transaction, approved by the Board and Audit Committee, reflects confidence in NKGen’s potential and aligns with the company’s strategic objectives.
More about NKGen Biotech
NKGen Biotech, Inc. is a clinical-stage biotechnology company based in Santa Ana, California, focused on the development and commercialization of innovative autologous and allogeneic natural killer (NK) cell therapeutics.
Average Trading Volume: 3,820,537
Technical Sentiment Signal: Sell
Current Market Cap: $5.95M
Find detailed analytics on NKGN stock on TipRanks’ Stock Analysis page.